Figure 1.
Pelvic computed tomography of the RA patient with factor XIII deficiency.
The white arrow indicates the intra-pelvic hemorrhage. (a) Transverse plane and (b) coronal plane.
Table 1.
Coagulation tests in the RA patient with factor XIII deficiency.
Table 2.
Comparison of the baseline RA patient characteristics.
Figure 2.
Comparison of the plasma factor XIII activity levels in the healthy controls and RA patients.
** the Steel-Dwass method (P<0.01). MTX, methotrexate; TNFi, tumor necrosis factor inhibitors; TCZ, tocilizumab.
Figure 3.
Plasma factor XIII quantitative concentrations in the RA patients treated with biologics.
(a) The relationship between the factor XIII activity levels and plasma concentrations was assessed according to Pearson's correlation coefficient. (r = 0.449, P = 0.019). (b) Comparison of the plasma factor XIII concentrations between the RA patients treated with TNFi and those treated with tocilizumab. * Student's t-test (P<0.05). TNFi, tumor necrosis factor inhibitors; TCZ, tocilizumab.
Table 3.
Single regression analyses between the factor XIII activity levels and the independent variables.
Table 4.
The multiple regression analysis of the independent risk factors for the factor XIII activity level depression.